A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation

Published:2016-07-18 Issue:1 Volume:52 Page:59-65
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Magenau J,Westervelt P,Khaled S,McGuirk J,Hari P,Eapen M,Becker P S,Parkin B,Braun T,Logan B,Wang H,Jagasia M,Rowley S D,Kim D D H,Schechter T,Frey N,Scott B,Churay T,Lieland S,Forman S,Mineishi S

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2016188.pdf

Reference35 articles.

1. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249–1259.

2. Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M et al. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol 1992; 81: 170–177.

3. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841–2851.

4. Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998; 28: 315–327.

5. Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1431–1438.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis;Annals of Hematology;2024-02-23

2. Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia;International Journal of Molecular Sciences;2024-01-12

3. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies;Transplantation and Cellular Therapy;2023-02

4. Salvaging (with) CloBu4;Transplantation and Cellular Therapy;2023-02

5. Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment;Annals of Hematology;2023-01-12